EVO101 / Evommune, Eli Lilly - LARVOL DELTA

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Virginia Clinical Research, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Virginia Clinical Research, Inc.

New P1 trial • Dermatology • Hidradenitis Suppurativa • Immunology

Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan (PRNewswire) - "Separately, following a review of results from its Phase 2a trial evaluating the safety and efficacy of a small molecule interleukin 1 receptor-associated kinase 4 (IRAK4) inhibitor, EVO101, in adults with mild-to-moderate AD, Evommune has decided to discontinue development of the program in AD and focus its resources on advancing its pipeline of systemically administered product candidates which have multiple milestones expected over the next several years."

Discontinued • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=119 | Completed | Sponsor: Evommune, Inc. | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=118 | Active, not recruiting | Sponsor: Evommune, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

EVO101 is a Novel, Topically Applied IRAK4 Inhibitor that can Suppress Inflammation in Human Skin Tissue Models (FOCIS 2023) - No abstract available

Dermatitis • Immunology • Inflammation • IRAK4

Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases (PRNewswire) - "Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing....The capital raised will support Evommune's three prioritized pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of the IRAK4."

Financing • Immunology • Inflammation

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=118 | Recruiting | Sponsor: Evommune, Inc.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology